Oscar Health, Inc.
boothcheck covers Oscar Health, Inc. (OSCR) but does not put one priced-in number on it: here the defensible answer is the evidence rather than a point estimate. boothcheck publishes no house fair value, target price, or buy/sell rating. Narrative composed June 27, 2026.
- The one number that decides Oscar is the medical loss ratio. Q1 2026 came in at 70.5%, and full-year guidance sits at 82.4% to 83.4%. The whole bull-versus-bear argument is whether the company keeps claims below the premiums it collects as it scales. - The price asks a lot of the balance sheet. At about 5.6x book, the multiple sits at the very top of the peer group and embeds a return on capital so high it cannot be expressed as a single sustainable figure. That is the disconnect: a thin equit
Is OSCR overvalued? See what's priced in →
317 institutional managers reported holding OSCR in 13F filings for the quarter ended 2026-03-31. Together they hold about 53% of the company; the top 10 hold 28%. 52 opened new positions that quarter. Held by Vanguard Group, BlackRock, D. E. Shaw, among others. On the short side, 17.5M shares were sold short as of the 2026-06-15 count, about 5% of shares outstanding (2 days of typical volume to cover).
Quarterly 13F filings arrive up to 45 days after quarter end, so the picture is never current (filed through 2026-05-29). Nothing here is investment advice.
OSCR's share count grew 43.7% over the past five years. It pays no dividend.
Share counts are split-adjusted; repurchase totals are gross of share issuance. Nothing here is investment advice.
Open-market insider buys at OSCR over the trailing three years: 2024: 14 buys totaling $46.13M. 21 officers and directors are on file.
Code P open-market purchases from SEC Form 4 filings, non-derivative, excluding scheduled 10b5-1 plans. Nothing here is investment advice.
OSCR's recent reports: the day-one move, then what the following quarter actually did.
| report | day one | next quarter |
|---|---|---|
| 2023-08-10 | +8.6% | -32.4% |
| 2023-11-08 | +23.5% | +37.0% |
| 2024-02-16 | +22.7% | -9.8% |
| 2024-05-08 | +9.3% | -21.0% |
Day-one is the close-to-close move around the filing. Nothing here is investment advice.
OSCR's latest 8-K filings: 2026-08-06 (items 2.02, 9.01); 2026-06-09 (items 5.07); 2026-06-08 (items 7.01); 2026-06-02 (items 5.02); 2026-05-06 (items 2.02, 9.01).
Item codes are the SEC's own classification of what each report discloses. Dates link to the filing on EDGAR. Nothing here is investment advice.
Model solve date: 2026-Q2
Narrative composed: June 27, 2026
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.